© 2026 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 4 Bouverie Street, London, EC4Y 8AX. Part of the Delinian group. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

Switzerland

  • FIG
    Commerzbank analysts had been expecting a “very constructive market” in Swiss francs this week, bolstered by supportive cross-currency swaps and an uptick in the secondary market. It is questionable, however, if anybody foresaw the explosion of volume on Tuesday, when more than Sfr1bn ($997m) of new issuance had been priced by early afternoon.
  • Shares in Medacta Group, the Swiss maker of orthopaedic devices controlled by the Siccardi family, rose in the aftermarket on Thursday morning after a popular Sfr547m IPO that has been described as “textbook” by a banker at one of the global coordinators.
  • Medacta, the Swiss maker of orthopaedic devices, has covered its Sfr550m IPO within the revised price range on the penultimate day of the bookbuild, according to a banker involved in the deal.
  • The IPO of Stadler Rail, the Swiss train manufacturer, is already covered after opening the books on its Sfr1.4bn IPO on the SIX Swiss Exchange on Monday morning, according to a banker involved in the deal.
  • Abegg Holding, the Swiss family office for Annina Müller‐Bodmer, gave the market an extremely rare liquidity event on Monday night by selling its entire stake in Huber + Suhner, the Swiss maker of fibre optic cables, for Sfr152m ($153m) following a prolonged share price rally.
  • Medacta, a manufacturer of orthopaedic devices, was covered within hours of setting the terms on its Swiss IPO, valuing the company at up to Sfr2.08bn.
  • Stadler Rail, the Swiss train maker, is gearing up for an IPO on the SIX Swiss Exchange in April, having filed an intention to float document on Tuesday.
  • Medacta, the Swiss maker of artificial human joints, has begun a process to list on the SIX Swiss Exchange before Easter. If it succeeds, it would be the first major company to complete an IPO in Europe this year.
  • Two emerging market borrowers familiar to investors returned to the Swiss franc market this week, injecting some geographical diversity into the sector.
  • Switzerland’s Roche has agreed to buy US company Spark Therapeutics for around $4.8bn, with analysts predicting minimal impact on the healthcare multinational’s credit metrics thanks to large forecasted free cash flow.
  • FFP Holdings, the investment vehicle linked with the Peugeot family, has sold its remaining stake in DKSH, a Swiss company that offers outsourcing services to others looking to expand their businesses, especially in Asia.
  • Barry Callebaut has taken €600m across three tranches in one of the biggest international Schuldschein transactions in the last 12 months. The Belgian-French chocolate company now based in Switzerland had roadshowed for a public benchmark sustainable bond in November, but opted instead for its first Schuldschein deal, as the risks of execution in the public market were too great.